Key Insights

Highlights

Success Rate

67% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 47/100

Termination Rate

15.2%

5 terminated out of 33 trials

Success Rate

66.7%

-19.9% vs benchmark

Late-Stage Pipeline

3%

1 trials in Phase 3/4

Results Transparency

90%

9 of 10 completed with results

Key Signals

9 with results67% success

Data Visualizations

Phase Distribution

20Total
Not Applicable (3)
P 1 (9)
P 2 (7)
P 3 (1)

Trial Status

Completed10
Recruiting9
Terminated5
Not Yet Recruiting3
Active Not Recruiting3
Unknown2

Trial Success Rate

66.7%

Benchmark: 86.5%

Based on 10 completed trials

Clinical Trials (33)

Showing 20 of 20 trials
NCT04557969Recruiting

Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis

NCT07724626Not Yet Recruiting

Hyperpolarized MRI for GIST on Imatinib

NCT07697248Recruiting

LRG GIST Patient Registry

NCT04821895Active Not RecruitingPrimary

Oncogenetic Panel and Integrated Clinical Data Registry Study for Wild Type Gastrointestinal Stromal Tumor Patients

NCT05489237Phase 1Active Not Recruiting

First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

NCT07673861Not ApplicableRecruiting

Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients

NCT07550582Phase 2Enrolling By Invitation

Mesenteric Vascular Preconditioning Combined With Laparoscopic and Endoscopic Cooperative Surgery for Submucosal Tumor at the Gastroesophageal Junction

NCT03594422Phase 1RecruitingPrimary

A Study of HQP1351 in Patients With GIST or Other Solid Tumors

NCT06630234Phase 1RecruitingPrimary

A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)

NCT06655246Phase 1RecruitingPrimary

A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

NCT01048281Recruiting

Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

NCT01991379Phase 1Active Not RecruitingPrimary

MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

NCT07109024Not Yet RecruitingPrimary

Resistance Profiling Using Functional Imaging and Next Generation Sequencing in Refractory Gastrointestinal Stomal Tumors (GIST)

NCT07106411Not Yet Recruiting

CEH-EUS for Differentiating GISTs and Leiomyomas: A Multicenter Prospective Self-Controlled Study

NCT07078136Recruiting

Multicenter Observational Study of Multimodal AI for Upper GI Mesenchymal Tumor Diagnosis

NCT07072143Recruiting

An International Study on Pediatric Patients With Rare Tumors.

NCT00780494Phase 2Completed

Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma

NCT01294202Phase 2CompletedPrimary

A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST

NCT01034670Not ApplicableTerminated

Advanced Gastrointestinal Endoscopic Imaging

NCT05453292Not ApplicableUnknownPrimary

Endoscopic Ultrasound Radiofrequency Ablation for GISTs

Scroll to load more

Research Network

Activity Timeline